Control of Line Complications with KiteLock (CLiCK) in the critical care unit: study protocol for a multi-center, cluster-randomized, double-blinded, crossover trial investigating the effect of a novel locking fluid on central line complications in the critical care population

Marlena Ornowska, Hubert Wong, Yongdong Ouyang, Anish Mitra, Aaron White, Sue Willems, Jessica Wittmann, Steven Reynolds, Marlena Ornowska, Hubert Wong, Yongdong Ouyang, Anish Mitra, Aaron White, Sue Willems, Jessica Wittmann, Steven Reynolds

Abstract

Background: Insertion of a central venous access device (CVAD) allows clinicians to easily access the circulation of a patient to administer life-saving interventions. Due to their invasive nature, CVADs are prone to complications such as bacterial biofilm production and colonization, catheter-related bloodstream infection, occlusion, and catheter-related venous thrombosis. A CVAD is among the most common interventions for patients in the intensive care unit (ICU), exposing this vulnerable population to the risk of nosocomial infection and catheter occlusion. The current standard of care involves the use of normal saline as a catheter locking solution for central venous catheters (CVCs) and peripherally inserted central catheter (PICC) lines, and a citrate lock for hemodialysis catheters. Saline offers little prophylactic measures against catheter complications. Four percent of tetrasodium ethylenediaminetetraacetic acid (EDTA) fluid (marketed as KiteLock Sterile Locking Solution™) is non-antibiotic, possesses antimicrobial, anti-biofilm, and anti-coagulant properties, and is approved by Health Canada as a catheter locking solution. As such, it may be a superior CVAD locking solution than the present standard of care lock in the ICU patient population.

Methods: Our team proposes to fill this knowledge gap by performing a multi-center, cluster-randomized, crossover trial evaluating the impact of 4% tetrasodium EDTA on a primary composite outcome of the incidence rate of central line-associated bloodstream infection (CLABSI), catheter occlusion leading to removal, and use of alteplase to resolve catheter occlusion compared to the standard of care. The study will be performed at five critical care units.

Discussion: If successful, the results of this study can serve as evidence for a shift of standard of care practices to include EDTA locking fluid in routine CVAD locking procedures. Completion of this study has the potential to improve CVAD standard of care to become safer for patients, as well as provides an opportunity to decrease strain on healthcare budgets related to treating preventable CVAD complications. Success and subsequent implementation of this intervention in the ICU may also be extrapolated to other patient populations with heavy CVAD use including hemodialysis, oncology, parenteral nutrition, and pediatric patient populations. On a global scale, eradicating biofilm produced by antibiotic-resistant bacteria may serve to lessen the threat of "superbugs" and contribute to international initiatives supporting the termination of antibiotic overuse.

Trial registration: ClinicalTrials.gov NCT04548713, registered on September 9th, 2020.

Keywords: Alteplase; Biofilm; Catheter colonization; Catheter locking; Catheter-related venous thrombosis; Central line-associated bloodstream infection; Central venous access device; Central line occlusion; Clinical trial; Intensive care unit.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Study protocol

References

    1. Frasca D, Dahyot-Fizelier C, Mimoz O. Prevention of central venous catheter-related infection in the intensive care unit. Crit Care. 2010;14(2):212. doi: 10.1186/cc8853.
    1. Takashima M, Schults J, Mihala G, Corley A, Ullman A. Complication and failures of central vascular access device in adult critical care settings*. Crit Care Med. 2018;46(12):1998–2009. doi: 10.1097/CCM.0000000000003370.
    1. Dudeck MA, Edwards JR, Allen-Bridson K, Gross C, Malpiedi PJ, Peterson KD, et al. National Healthcare Safety Network report, data summary for 2013, device-associated module. Am J Infect Control. 2015;43(3):206–221. doi: 10.1016/j.ajic.2014.11.014.
    1. Holton D, Paton S, Conly J, Embree J, Taylor G, Thompson W, et al. Central venous catheter-associated blood stream infections occurring in Canadian intensive care units: a six-month cohort study. Can J Infect Dis Med Microbiol. 2006;17(3):169–176. doi: 10.1155/2006/781735.
    1. Ryder M. Catheter-related infections: it’s all about biofilm. Top Adv Pract Nurs eJ. 2005;5(3):1–6.
    1. Laupland KB, Lee H, Gregson DB, Manns BJ. Cost of intensive care unit-acquired bloodstream infections. J Hosp Infect. 2006;63(2):124–132. doi: 10.1016/j.jhin.2005.12.016.
    1. Central venous catheter-associated blood stream infections in intensive care units in Canadian acute-care hospital. . Accessed 21 Mar 2022.
    1. Ryder M. The role of biofilm in vascular catheter-related infections. N Dev Vasc Dis. 2001;2:15–25.
    1. Burns KEA, McLaren A. A critical review of thromboembolic complications associated with central venous catheters. Can J Anesth. 2008;55(8):532–541. doi: 10.1007/BF03016674.
    1. Bagnall-Reeb H. Diagnosis of central venous access device occlusion. Implications for nursing practice. J Intraven Nurs. 1998;21(Suppl 5):S115–S121.
    1. Baskin JL, Reiss U, Wilimas JA, Metzger ML, Ribeiro RC, Pui C-H, et al. Thrombolytic therapy for central venous catheter occlusion. Haematologica. 2012;97(5):641–650. doi: 10.3324/haematol.2011.050492.
    1. Ernst FR, Chen E, Lipkin C, Tayama D, Amin AN. Comparison of hospital length of stay, costs, and readmissions of alteplase versus catheter replacement among patients with occluded central venous catheters: outcomes in CVC Occlusions. J Hosp Med. 2014;9(8):490–496. doi: 10.1002/jhm.2208.
    1. Kleindorfer D, Broderick J, Demaerschalk B, Saver J. Cost of alteplase has more than doubled over the past decade. Stroke. 2017;48(7):2000–2002. doi: 10.1161/STROKEAHA.116.015822.
    1. Ahmed I, Majeed A, Powell R. Heparin induced thrombocytopenia: diagnosis and management update. Postgrad Med J. 2007;83(983):575–582. doi: 10.1136/pgmj.2007.059188.
    1. Shanks RMQ, Sargent JL, Martinez RM, Graber ML, O’Toole GA. Catheter lock solutions influence staphylococcal biofilm formation on abiotic surfaces. Nephrol Dial Transplant. 2006;21(8):2247–2255. doi: 10.1093/ndt/gfl170.
    1. Dal Molin A, Allara E, Montani D, Milani S, Frassati C, Cossu S, et al. Flushing the central venous catheter: is heparin necessary? J Vasc Access. 2014;15(4):241–248. doi: 10.5301/jva.5000225.
    1. López-Briz E, Ruiz Garcia V, Cabello JB, Bort-Marti S, Carbonell Sanchis R, Burls A. Heparin versus 0.9% sodium chloride intermittent flushing for prevention of occlusion in central venous catheters in adults. Cochrane Database Syst Rev. 2014;(10):CD008462.
    1. Zacharioudakis IM, Zervou FN, Arvanitis M, Ziakas PD, Mermel LA, Mylonakis E. Antimicrobial lock solutions as a method to prevent central line–associated bloodstream infections: a meta-analysis of randomized controlled trials. Clin Infect Dis. 2014;59(12):1741–1749. doi: 10.1093/cid/ciu671.
    1. Wolf J, Connell TG, Allison KJ, Tang L, Richardson J, Branum K, et al. Treatment and secondary prophylaxis with ethanol lock therapy for central line-associated bloodstream infection in paediatric cancer: a randomised, double-blind, controlled trial. Lancet Infect Dis. 2018;18(8):854–863. doi: 10.1016/S1473-3099(18)30224-X.
    1. Pérez-Granda MJ, Barrio JM, Muñoz P, Hortal J, Rincón C, Rabadán PM, et al. Ethanol lock therapy (E-Lock) in the prevention of catheter-related bloodstream infections (CR-BSI) after major heart surgery (MHS): a randomized clinical trial. PLoS One. 2014;9(3):e91838. doi: 10.1371/journal.pone.0091838.
    1. Schallom ME, Prentice D, Sona C, Micek ST, Skrupky LP. Heparin or 0.9% sodium chloride to maintain central venous catheter patency: a randomized trial. Crit Care Med. 2012;40(6):1820–1826. doi: 10.1097/CCM.0b013e31824e11b4.
    1. Quenot J-P, Helms J, Bourredjem A, Dargent A, Meziani F, Badie J, et al. Trisodium citrate 4% versus heparin as a catheter lock for non-tunneled hemodialysis catheters in critically ill patients: a multicenter, randomized clinical trial. Ann Intensive Care. 2019;9(1):75. doi: 10.1186/s13613-019-0553-4.
    1. Banfi G, Salvagno GL, Lippi G. The role of ethylenediamine tetraacetic acid (EDTA) as in vitro anticoagulant for diagnostic purposes. Clin Chem Lab Med. 2007;45(5):565–576. doi: 10.1515/CCLM.2007.110.
    1. Finnegan S, Percival SL. EDTA: an antimicrobial and antibiofilm agent for use in wound care. Adv Wound Care. 2015;4(7):415–421. doi: 10.1089/wound.2014.0577.
    1. Liu F, Hansra S, Crockford G, Köster W, Allan BJ, Blondeau JM, et al. Tetrasodium EDTA is effective at eradicating biofilms formed by clinically relevant microorganisms from patients’ central venous catheters. mSphere. 2018;3(6):e00525–e00518. doi: 10.1128/mSphere.00525-18.
    1. Kanaa M, Wright MJ, Akbani H, Laboi P, Bhandari S, Sandoe JAT. Cathasept line lock and microbial colonization of tunneled hemodialysis catheters: a multicenter randomized controlled trial. Am J Kidney Dis. 2015;66(6):1015–1023. doi: 10.1053/j.ajkd.2015.04.047.
    1. Quirt J, Belza C, Pai N, Clause R-F, Markovic F, Wong-Sterling S, et al. Reduction of central line-associated bloodstream infections and line occlusions in pediatric intestinal failure patients receiving long-term parenteral nutrition using an alternative locking solution, 4% tetrasodium ethylenediaminetetraacetic acid. JPEN J Parenter Enteral Nutr. 2021;45(6):1286–1292. doi: 10.1002/jpen.1989.
    1. Hill J, Garner R. Efficacy of 4% tetrasodium ethylenediaminetetraacetic acid (T-EDTA) catheter lock solution in home parenteral nutrition patients: a quality improvement evaluation. J Vasc Access. 2021;22(4):533–539. doi: 10.1177/1129729820946916.
    1. National Healthcare Safety Network (NHSN) patient safety component manual. . Accessed 21 Mar 2022.
    1. Canadian Nosocomial Infection Surveillance Program Surveillance for Central Line Associated Blood Stream Infections (CLABSI) in intensive care units (ICUs). Public Health Agency of Canada; 2021. . Accessed 21 Mar 2022.
    1. Mermel LA, Allon M, Bouza E, Craven DE, Flynn P, O’Grady NP, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1–45. doi: 10.1086/599376.
    1. Ornowska M, Wittmann J, Reynolds S. Central venous access device locking practices in the adult critical care setting: A single-centre, observational study establishing duration of locking per catheter lumen. Vasc Access J Can Vasc Access Assoc. 2022;16(2):10–21.
    1. Hemming K, Kasza J, Hooper R, Forbes A, Taljaard M. A tutorial on sample size calculation for multiple-period cluster randomized parallel, cross-over and stepped-wedge trials using the Shiny CRT Calculator. Int J Epidemiol. 2020;49(3):979–995. doi: 10.1093/ije/dyz237.
    1. Rothman KJ, Lash TL, VanderWeele TJ, Haneuse S. Modern epidemiology. 4. Philadelphia: Wolters Kluwer; 2021.
    1. Shanmugasundaram S, Kubiak A, Dar A, Shrinet A, Chauhan N, Haque H, et al. High incidence of large bore temporary hemodialysis catheter malfunction in patients with COVID-19 related kidney injury. J Vasc Access. 2022:112972982110673.
    1. Kanitra JJ, Power AD, Hayward RD, Haouilou JC, Edhayan E. Malfunctioning temporary hemodialysis catheters in patients with novel coronavirus disease 2019. J Vasc Surg. 2021;73(6):1881–1888.e3. doi: 10.1016/j.jvs.2020.11.033.
    1. Gidaro A, Vailati D, Gemma M, Lugli F, Casella F, Cogliati C, et al. Retrospective survey from vascular access team Lombardy net in COVID-19 era. J Vasc Access. 2021:1129729821997252.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する